Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Annovis Bio, Inc.
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
October 22, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
October 15, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
October 03, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
October 02, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
September 30, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Reports Second Quarter Financial Results and Provides Business Update
August 15, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
August 06, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
July 24, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
July 16, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
July 09, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
July 02, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
June 27, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Files Patent for New Composition of Matter for Buntanetap
June 26, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
June 25, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference® 2024
June 18, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
June 11, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
June 05, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Announces Pricing of $7.5 Million Public Offering
October 31, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Announces Launch of Proposed Public Offering
October 30, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
October 30, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
October 24, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 15, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
July 18, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Announces the Filing of a Groundbreaking Patent
June 27, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
June 20, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.